ECM
FSTX

Endurant Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Endurant Capital Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,445
Closed -$202K – 76
2020
Q4 		$202K Buy
+20,445
New +$134K 0.07% 52

Other funds holding FSTX

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Endurant Capital Management's FSTX Position: Q1 2021 in Review

Endurant Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2021, closing a stake of 20,445 shares — an estimated $202K sold.

Endurant Capital Management first reported a position in FSTX in Q4 2020 and held it in 1 quarter. The position peaked at $202K in Q4 2020. 26 funds tracked by Wall St. Rank hold FSTX as of Q1 2021.

  • Endurant Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Endurant Capital Management sold 20,445 F-star Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $202K.
  • Endurant Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Endurant Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $202K in Q4 2020.
  • 26 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.